Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism in healthy individuals without symptoms of arthritis: A randomized double‑blind placebo‑controlled clinical study

Tomonaga,Akihito; Watanabe,Keita; Fukagawa,Mitsuhiko; Suzuki,Asahi; Kurokawa,Mihoko; Nagaoka,Isao

doi:10.3892/etm.2016.3480

Evaluation of the effect of N-acetyl-glucosamine administration on biomarkers for cartilage metabolism in healthy individuals without symptoms of arthritis: A randomized double‑blind placebo‑controlled clinical study

Authors:
- Akihito Tomonaga
- Keita Watanabe
- Mitsuhiko Fukagawa
- Asahi Suzuki
- Mihoko Kurokawa
- Isao Nagaoka
View Affiliations

Affiliations: Tana Orthopedic Surgery, Kanagawa 227-0064, Japan, Kitashinyokohama Orthopedic Surgery, Kanagawa 222‑0059, Japan, Q'sai Co., Ltd., Fukuoka 810‑8606, Japan, Department of Host Defense and Biochemical Research, Graduate School of Medicine, Juntendo University, Tokyo 113‑8421, Japan
Published online on: June 24, 2016 https://doi.org/10.3892/etm.2016.3480
Pages: 1481-1489

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to evaluate the effect of N‑acetyl‑glucosamine (GlcNAc) on the joint health of healthy individuals without arthritic symptoms. A randomized double‑blind placebo‑controlled clinical trial was performed to investigate the effect of oral administration of a GlcNAc‑containing test supplement (low dose, 500 mg/day and high dose, 1,000 mg/day) on cartilage metabolism in healthy individuals with a mean age of 48.6±1.3 years (range, 23‑64 years) by analyzing the ratio of type II collagen degradation to type II collagen synthesis using type II collagen degradation (C2C) and synthesis (PIICP) markers. The results indicated that the changes in C2C/PIICP ratios from the baseline were suppressed in the treated with low and high doses of GlcNAc, compared with the placebo group at week 16 during intervention. To further elucidate the effect of GlcNAc, subjects with impaired cartilage metabolism were evaluated. Notably, the changes in the C2C/PIICP ratios were markedly suppressed in the groups treated with low and high doses of GlcNAc at week 16. Finally, to exclude the effect of heavy body weight on joint loading, subjects weighing <70 kg with impaired cartilage metabolism were analyzed. Notably, the changes in the C2C/PIICP ratios were suppressed in the groups treated with low and high doses of GlcNAc at weeks 12 and 16. No test supplement‑related adverse events were observed during or following the intervention. Together, these observations suggest that oral administration of GlcNAc at doses of 500 mg and 1,000 mg/day exhibits a chondroprotective effect on healthy individuals by reducing the C2C/PIICP ratio (relatively decreasing type II collagen degradation and increasing type II collagen synthesis) without any apparent adverse effects.

View Figures

View References

1	Ravenda V, Manette C, Lemmens R, Mariani AM, Struvay N and Reginster JY: Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects. Aging Clin Exp Res. 19:55–60. 2007. View Article : Google Scholar : PubMed/NCBI
2	Jinks C, Jordan K and Croft P: Osteoarthritis as a public health problem: The impact of developing knee pain on physical function in adults living in the community: (KNEST 3). Rheumatology (Oxford). 46:877–881. 2007. View Article : Google Scholar : PubMed/NCBI
3	Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, et al: Prevalence of knee osteoarthritis, lumbar spondylosis and osteoporosis in Japanese men and women: The research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab. 27:620–628. 2009. View Article : Google Scholar : PubMed/NCBI
4	Qi C and Changlin H: Effects of moving training on histology and biomarkers levels of articular cartilage. J Surg Res. 135:352–363. 2006. View Article : Google Scholar : PubMed/NCBI
5	Garnero P, Rousseau JC and Delmas PD: Molecular basis and clinical use of biochemical markers of bone, cartilage and synovium in joint diseases. Arthritis Rheum. 43:953–968. 2000. View Article : Google Scholar : PubMed/NCBI
6	Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD and Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage and synovial tissue metabolism in patients with knee osteoarthritis: Relations with disease activity and joint damage. Ann Rheum Dis. 60:619–626. 2001. View Article : Google Scholar : PubMed/NCBI
7	Poole AR: Biochemical/immunochemical biomarkers of osteoarthritis: Utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am. 29:803–818. 2003. View Article : Google Scholar : PubMed/NCBI
8	Rousseau JC and Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 3:346–356. 2007. View Article : Google Scholar : PubMed/NCBI
9	Garnero P and Delmas PD: Biomarkers in osteoarthritis. Curr Opin Rheumatol. 15:641–646. 2003. View Article : Google Scholar : PubMed/NCBI
10	Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C and Qvist P: Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 29:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
11	Poole AR, Ionescu M, Fitzcharles MA and Billinghurst RC: The assessment of cartilage degradation in vivo: Development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods. 294:145–153. 2004. View Article : Google Scholar : PubMed/NCBI
12	Shinmei M, Ito K, Matsuyama S, Yoshihara Y and Matsuzawa K: Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage. 1:121–128. 1993. View Article : Google Scholar : PubMed/NCBI
13	Schwenk TL and Costley CD: When food becomes a drug: Nonanabolic nutritional supplement use in athletes. Am J Sports Med. 30:907–916. 2002.PubMed/NCBI
14	Gorsline RT and Kaeding CC: The use of NSAIDs and nutritional supplements in athletes with osteoarthritis: Prevalence, benefits and consequences. Clin Sports Med. 24:71–82. 2005. View Article : Google Scholar : PubMed/NCBI
15	Ostojic SM, Arsic M, Prodanovic S, Vukovic J and Zlatanovic M: Glucosamine administration in athletes: Effects on recovery of acute knee injury. Res Sports Med. 15:113–124. 2007. View Article : Google Scholar : PubMed/NCBI
16	Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP and Orth MW: Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage. 8:258–265. 2000. View Article : Google Scholar : PubMed/NCBI
17	Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, Fournel-Gigleux S and Ouzzine M: Interleukin-1beta downregulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: Influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum. 44:351–360. 2001. View Article : Google Scholar : PubMed/NCBI
18	Nakamura H, Shibakawa A, Tanaka M, Kato T and Nishioka K: Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol. 22:293–299. 2004.PubMed/NCBI
19	Derfoul A, Miyoshi AD, Freeman DE and Tuan RS: Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage. 15:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
20	McAlindon TE, Lavalley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA. 283:1469–1475. 2000. View Article : Google Scholar : PubMed/NCBI
21	Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomized, placebo-controlled clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar : PubMed/NCBI
22	Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162:2113–2123. 2002. View Article : Google Scholar : PubMed/NCBI
23	Momomura R, Naito K, Igarashi M, Watari T, Terakado A, Oike S, Sakamoto K, Nagaoka I and Kaneko K: Evaluation of the effect of glucosamine administration on biomarkers of cartilage and bone metabolism in bicycle racer. Mol Med Report. 7:742–746. 2013.
24	Shikhman AR, Brinson DC, Valbracht J and Lotz MK: Differential metabolic effects of glucosamine and N-acetylglucosamine in human articular chondrocytes. Osteoarthritis Cartilage. 17:1022–1028. 2009. View Article : Google Scholar : PubMed/NCBI
25	Shikhman AR, Kuhn K, Alaaeddine N and Lotz M: N-acetylglucosamine prevents IL-1beta-mediated activation of human chondrocytes. J Immunol. 166:5155–5160. 2001. View Article : Google Scholar : PubMed/NCBI
26	Shikhman AR, Amiel D, D'Lima D, Hwang SB, Hu C, Xu A, Hashimoto S, Kobayashi K, Sasho T and Lotz MK: Chondroprotective activity of N-acetylglucosamine in rabbits with experimental osteoarthritis. Ann Rheum Dis. 64:89–94. 2005. View Article : Google Scholar : PubMed/NCBI
27	Ozkan FU, Ozkan K, Ramadan S and Guven Z: Chondroprotective effect of N-acetylglucosamine and hyaluronate in early stages of osteoarthritis: An experimental study in rabbits. Bull NYU Hosp Jt Dis. 67:352–357. 2009.PubMed/NCBI
28	Katsuno S, Sato K, Eguchi C, Yoshimura K, Yamamoto T, Tomonaga A and Nagaoka I: Effects and safety of bilk beverage containing N-acetyl glucosamine on knee joint pain and biomarkers of type II collagen metabolism. Jpn Pharmacol Ther. 38:435–445. 2010.
29	Kellgren JH and Lawrence JS: Radiological assessment of osteo-arthritis. Ann Rheum Dis. 16:494–502. 1957. View Article : Google Scholar : PubMed/NCBI
30	Cahue S, Sharma L, Dunlop D, Ionescu M, Song J, Lobanok T, King L and Poole AR: The ratio of type II collagen breakdown to synthesis and its relationship with the progression of knee osteoarthritis. Osteoarthr Cartilage. 15:819–823. 2007. View Article : Google Scholar
31	Sharif M, Kirwan J, Charni N, Sandell LJ, Whittles C and Garnero P: A 5-yr longitudinal study of type IIA collagen synthesis and total type II collagen degradation in patients with knee osteoarthritis-association with disease progression. Rheumatology (Oxford). 46:938–943. 2007. View Article : Google Scholar : PubMed/NCBI
32	Christgau S, Henrotin Y, Tankó LB, Rovati LC, Collette J, Bruyere O, Deroisy R and Reginster JY: Osteoarthritic patients with high cartilage turnover show increased responsiveness to the cartilage protecting effects of glucosamine sulfate. Clin Exp Rheumatol. 22:36–42. 2004.PubMed/NCBI
33	Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, Pope J, Hong P, Grant E, Lobanok T, et al: Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: Randomized discontinuation trial results employing biomarkers. J Rheumatol. 32:896–902. 2005.PubMed/NCBI
34	Mazières B, Hucher M, Zaïm M and Garnero P: Effect of chondroitin sulfate in symptomatic knee osteoarthritis: A multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 66:639–645. 2007. View Article : Google Scholar : PubMed/NCBI
35	Julovi SM, Ito H, Nishitani K, Jackson CJ and Nakamura T: Hyaluronan inhibits matrix metalloproteinase-13 in human arthritic chondrocytes via CD44 and P38. J Orthop Res. 29:258–264. 2011. View Article : Google Scholar : PubMed/NCBI
36	Yatabe T, Mochizuki S, Takizawa M, Chijiiwa M, Okada A, Kimura T, Fujita Y, Matsumoto H, Toyama Y and Okada Y: Hyaluronan inhibits expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic chondrocytes. Ann Rheum Dis. 68:1051–1058. 2009. View Article : Google Scholar : PubMed/NCBI
37	Mladenovic Z, Saurel AS, Berenbaum F and Jacques C: Potential role of hyaluronic acid on bone in osteoarthritis: Matrix metalloproteinases, aggrecanases and RANKL expression are partially prevented by hyaluronic acid in interleukin 1-stimulated osteoblasts. J Rheumatol. 41:945–954. 2014. View Article : Google Scholar : PubMed/NCBI